





Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/067,996
Filing Date	February 8, 2002
First Named Inventor	Allen T. Hopper
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KH	2	THOMAS C. MCKENZIE et al., "The Gornberg-Bachmann Reaction of Purines", <u>J. Heterocyclic Chem.</u> , May-Jun 1987, pp. 859-861, Vol. 24	
	3	VASU NAIR et al., "Novel, Stable Congeners of Antiretroviral Compound 2', 3'- Dideoxyadenosine," <u>J. Am. Chem. Soc.</u> , 1989, pp. 8502-8504, Vol. 111	
	4	JAMES E. KELLEY et al., "Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifluoromethyl-9H-purines," <u>Eur. J. Med. Chem.</u> , 1990, pp. 131-135, Vol. 25	
	5	JEAN-JACQUES BOURGUIGNON et al., "9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors," <u>J. Med. Chem.</u> , 1997, pp. 1768-1770, Vol. 40	
	6	JAMES L. KELLEY et al., "6-(Alkylamino)-9-alkylpurines. A New Class of Potential Antipsychotic Agents," <u>J. Med. Chem.</u> , 1997, pp. 3207-3216, Vol. 40	
	7	ELISABETH BOICHOT et al., "Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9- Benzyladenine," <u>The Journal Of Pharmacology And Experimental Therapeutics</u> , 2000, pp. 647-653, Vol 292, No.2	
	8	V. VAIR, "Hydrolysis of Dideoxygenated Purine Nucleosides: Effect of Modification of the Base Moiety", <u>J. ORG. CHEM.</u> , 1990, pp. 3695-3697, vol. 55, no. 11	
	9	H. NAGANO et al., "Fluorine-Containing Potential Anticancer agents. II. Syntheses Trifluoromethylpurines and Trifluoromethylthiazolopyrimidines", <u>J. MED. CHEM.</u> , 1964, pp. 215-220, vol. 7, no. 2	
	10	VASU NAIR et al., "Inhibition of mammalian adenosine deaminase by novel functionalized 2', 3'- dideoxyadenosines", <u>BIOCHIM. BIOPHYS. ACTA</u> , 1991, pp. 121-123, vol. 1078, no. 1	
	11	PATENT ABSTRACTS OF JAPAN, vol. 2000, no. 6, September 22, 2000, JP 200 072773, March 7, 2000	
	12	PATENT ABSTRACTS OF JAPAN, vol. 1999, no. 12, October 29, 1999, JP 11 180982, July 6, 1999	

Examiner
Signature

A. K. Hopper

Date
Considered

June 12, 2003

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
NOV 07 2002
TECH CENTER 1600/2900